How HER2 status is determined and reported in breast (and gastric) cancer, using IHC and in-situ hybridization.
The standard for how HER2 status is tested and reported to guide HER2-targeted therapy.
Developed jointly by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP), this guideline standardises how HER2 (human epidermal growth factor receptor 2) status is tested and reported, primarily in breast cancer, with related principles applied in gastric cancer.
HER2 status helps guide whether a patient may benefit from HER2-targeted therapy. Consistent testing and scoring reduce the risk of false-positive or false-negative results that could affect treatment decisions.
When HER2 testing is requested, our reporting follows the current ASCO–CAP interpretation and reflex-testing principles, so results are consistent and clinically actionable.
Tell us what you need, our team will help with sample requirements, turnaround, and reporting.